Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models.
The study suggests that DSIP-CBBBP may modulate neurotransmitter levels and enhance sleep in a mouse model, but specific outcomes are not detailed.
Where it sits
this study against the rest of the dsip corpusSummary and findings
This study investigates the effects of DSIP-CBBBP on sleep regulation and neurotransmitter levels in a PCPA-induced insomnia mouse model. The peptide demonstrated a capacity to modulate neurotransmitter levels, although specific numeric outcomes are not detailed in the abstract. No therapeutic claims are made.
Abstract
<h4>Background</h4><i>Pichia pastoris</i>-secreted delta sleep inducing peptide and crossing the blood-brain barrier peptides (DSIP-CBBBP) fusion peptides holds significant promise for its potential sleep-enhancing and neurotransmitter balancing effects. This study investigates these properties using a p-chlorophenylalanine (PCPA) -induced insomnia model in mice, an approach akin to traditional methods evaluating sleep-promoting activities in fusion peptides.<h4>Aim of the study</h4>The research aims to elucidate the sleep-promoting mechanism of DSIP-CBBBP, exploring its impact on neurotransmitter levels and sleep regulation, and to analyze its composition and structure.<h4>Materials and methods</h4>Using a PCPA-induced insomnia mouse model, the study evaluates the sleep-promoting effects of DSIP-CBBBP. The peptide's influence on neurotransmitters such as 5-HT, glutamate, dopamine, and melatonin is assessed. The functions of DSIP-CBBBP are characterized using biochemical and animal insomnia-induced behavior tests and compared without CBBBP.<h4>Results</h4>DSIP-CBBBP demonstrates a capacity to modulate neurotransmitter levels, indicated by changes in 5-HT, glutamate, DA, and melatonin. DSIP-CBBBP shows a better restorative effect than DSIP on neurotransmitter imbalance and the potential to enhance sleep.<h4>Conclusion</h4>The study underscores DSIP-CBBBP potential in correcting neurotransmitter dysregulation and promoting sleep, hinting at its utility in sleep-related therapies.
Background
The paper addresses the potential of DSIP fusion peptides to alleviate insomnia, a condition that affects a significant portion of the population. Prior research has suggested that peptides may have neuroactive properties, but their ability to cross the blood-brain barrier and exert effects in vivo has not been thoroughly explored. This study aims to fill that gap by examining the effects of these peptides in a specific mouse model of insomnia.
Methods
The study utilized a mouse model induced with insomnia via PCPA. The specific number of subjects (n), dosage of the DSIP fusion peptide, duration of treatment, and route of administration were not detailed in the abstract. Primary and secondary outcome measures were also not specified.
Results
Not reported in abstract.
Interpretation
Without specific results, it is difficult to compare the findings to existing literature or determine the clinical significance of any observed effects. The lack of reported numeric data raises concerns about the robustness of the conclusions drawn from this study. The use of a rodent model also limits the applicability of the findings to human populations.
Key findings
- Not reported in abstract.
Limitations
- Not reported in abstract.